ArticleThe Lancet regional health. Europe2025
Effectiveness of quadrivalent human papillomavirus vaccination against high-grade cervical lesions by age and doses: a population-based cohort study.
Article in The Lancet regional health. Europe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Knowledge and awareness of HPV vaccination uptake and recommendations in gulf cooperation council countries 2009-2025: a systematic review.Archives of public health = Archives belges de sante publique · 2026Pooled it
- A missed opportunity: faith leaders and the HPV vaccination effort in Addis Ababa, Ethiopia.Global health action · 2026Article
- How practically feasible is tailored screening for cervical cancer based on human papillomavirus vaccination status?: the role of data linkage and registers.Journal of the National Cancer Institute. Monographs · 2026Review
- Real-world Impact of HPV Vaccination on CIN2+ Reduction: A Meta-analysis of Observational Studies Assessing Variation by Age, Coverage, and Vaccine Type.Open forum infectious diseases · 2026Review
- Prediction models for high-grade cervical lesions or worse using machine learning.EClinicalMedicine · 2026Article
- Extended follow-up of invasive cervical cancer risk after quadrivalent HPV vaccination: nationwide, register based study.BMJ (Clinical research ed.) · 2026Article
- Quadrivalent Human Papillomavirus Vaccine and High-Grade Vulvovaginal Lesions.JAMA oncology · 2026Article
- Silencing HPV: the rise of RNA therapeutics in cervical cancer.Infectious agents and cancer · 2026Review
- Cutaneous-Tropism Viruses: Unraveling Pathogenetic Mechanisms and Immunoprophylactic Strategies.Life (Basel, Switzerland) · 2026Review
- HPV vaccination associates withFrontiers in microbiology · 2026Article
- Immunopersistence of one or two doses of an Escherichia coli produced bivalent HPV vaccine.NPJ vaccines · 2025Article
- Human papillomavirus (HPV) genotypes extended prevalence in the female population from a city in Northern Chile.BMC women's health · 2025Article
- Human Papillomavirus: An Old New History.Pathogens (Basel, Switzerland) · 2025Review
- Early and long-term effects of prophylactic and post-excision human papillomavirus vaccination on recurrent high-grade cervical intraepithelial neoplasia relative to margin status: a retrospective cohort study in the Czech Republic.The Lancet regional health. Europe · 2025Article
- Exploring Ukrainian Refugee Women's Beliefs and Concerns About Healthcare Systems, with a Focus on HPV Immunization Practices: A Mixed-Methods Study on Forcibly Displaced Populations in Romania.Healthcare (Basel, Switzerland) · 2025Article
- The effect of bivalent HPV vaccination against invasive cervical cancer and cervical intraepithelial neoplasia grade 3 (CIN3+) in the Netherlands: a population-based linkage study.The Lancet regional health. Europe · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: One or two-dose schedule for human papillomavirus (HPV) vaccination has been recommended by the World Health Organization and used in many vaccination programs. We aimed to comprehensively evaluate the effectiveness of quadrivalent HPV vaccine against high-grade cervical lesions by age at vaccination and number of doses received. Methods: This cohort study included 2,200,495 females aged 10-35 years old who were residents of Sweden between 2006 and 2022, with 584,676 (26.6%) receiving at least one dose of quadrivalent HPV vaccine. We used Poisson regression models to estimate the incidence rate ratios (IRR) comparing the incidence rate of high-grade cervical lesions in relation to age at vaccination and doses. Findings: In girls initiating vaccination before age 15, we observed IRRs of 0.42 (95% CI 0.33-0.52) after one-dose, 0.54 (0.47-0.63) after two-dose, and 0.50 (0.47-0.53) after three-dose. The IRRs were 0.60 (95% CI 0.52-0.70), 0.55 (0.49-0.62), and 0.54 (0.52-0.56) after one, two or three doses for girls who initiated vaccination age 15-17. For women who initiated vaccination after age 20, higher doses may be needed to achieve a statistically significant risk reduction. Interpretation: Receiving one or two doses of HPV vaccines prior to age 17, especially for those initiating before age 15, has comparable effectiveness against high-grade cervical lesions with those who received three doses. Funding: Swedish Research Council, Swedish Research Council for Health, Working Life and Welfare, and Karolinska Institutet.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.